258 related articles for article (PubMed ID: 26536665)
21. Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.
Song X; Liu X; Wang H; Wang J; Qiao Y; Cigliano A; Utpatel K; Ribback S; Pilo MG; Serra M; Gordan JD; Che L; Zhang S; Cossu A; Porcu A; Pascale RM; Dombrowski F; Hu H; Calvisi DF; Evert M; Chen X
Clin Cancer Res; 2019 Jan; 25(1):403-413. PubMed ID: 30084835
[TBL] [Abstract][Full Text] [Related]
22. Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR
Hsu PY; Wu VS; Kanaya N; Petrossian K; Hsu HK; Nguyen D; Schmolze D; Kai M; Liu CY; Lu H; Chu P; Vito CA; Kruper L; Mortimer J; Chen S
Clin Cancer Res; 2018 Jan; 24(2):395-406. PubMed ID: 29079660
[No Abstract] [Full Text] [Related]
23. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma.
Lin Z; McDermott A; Shao L; Kannan A; Morgan M; Stack BC; Moreno M; Davis DA; Cornelius LA; Gao L
Cancer Lett; 2014 Mar; 344(2):272-281. PubMed ID: 24262658
[TBL] [Abstract][Full Text] [Related]
24. Survivin is a therapeutic target in Merkel cell carcinoma.
Arora R; Shuda M; Guastafierro A; Feng H; Toptan T; Tolstov Y; Normolle D; Vollmer LL; Vogt A; Dömling A; Brodsky JL; Chang Y; Moore PS
Sci Transl Med; 2012 May; 4(133):133ra56. PubMed ID: 22572880
[TBL] [Abstract][Full Text] [Related]
25. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
26. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Hernandez SF; Chisholm S; Borger D; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2016 Jun; 141(3):570-579. PubMed ID: 27017985
[TBL] [Abstract][Full Text] [Related]
27. Characterization of functional domains in the Merkel cell polyoma virus Large T antigen.
Houben R; Angermeyer S; Haferkamp S; Aue A; Goebeler M; Schrama D; Hesbacher S
Int J Cancer; 2015 Mar; 136(5):E290-300. PubMed ID: 25208506
[TBL] [Abstract][Full Text] [Related]
28. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
29. Simultaneously targeting DNA damage repair pathway and mTORC1/2 results in small cell lung cancer growth arrest via ER stress-induced apoptosis.
Fang B; Kannan A; Guo T; Gao L
Int J Biol Sci; 2018; 14(10):1221-1231. PubMed ID: 30123071
[No Abstract] [Full Text] [Related]
30. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
Iwasaki T; Matsushita M; Nonaka D; Kuwamoto S; Kato M; Murakami I; Nagata K; Nakajima H; Sano S; Hayashi K
Hum Pathol; 2015 Feb; 46(2):210-6. PubMed ID: 25466966
[TBL] [Abstract][Full Text] [Related]
31. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
Allen-Petersen BL; Risom T; Feng Z; Wang Z; Jenny ZP; Thoma MC; Pelz KR; Morton JP; Sansom OJ; Lopez CD; Sheppard B; Christensen DJ; Ohlmeyer M; Narla G; Sears RC
Cancer Res; 2019 Jan; 79(1):209-219. PubMed ID: 30389701
[TBL] [Abstract][Full Text] [Related]
32. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
Guo Y; Kwiatkowski DJ
Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
[TBL] [Abstract][Full Text] [Related]
33. The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results.
Gambichler T; Majchrzak-Stiller B; Peters I; Becker JC; Strotmann J; Abu Rached N; Müller T; Uhl W; Buchholz M; Braumann C
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10831-10840. PubMed ID: 37311987
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth.
Houben R; Hesbacher S; Sarma B; Schulte C; Sarosi EM; Popp S; Adam C; Kervarrec T; Schrama D
Cancer Lett; 2022 Jan; 524():259-267. PubMed ID: 34715251
[TBL] [Abstract][Full Text] [Related]
35. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.
Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK
Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606
[TBL] [Abstract][Full Text] [Related]
36. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling.
Martins C; Rasbach E; Heppt MV; Singh P; Kulcsar Z; Holzgruber J; Chakraborty A; Mucciarone K; Kleffel S; Brandenburg A; Hoetzenecker W; Rahbari NN; DeCaprio JA; Thakuria M; Murphy GF; Ramsey MR; Posch C; Barthel SR; Schatton T
Sci Adv; 2024 Jan; 10(3):eadi2012. PubMed ID: 38241371
[TBL] [Abstract][Full Text] [Related]
37. Merkel Cell Carcinoma Therapeutic Update.
Cassler NM; Merrill D; Bichakjian CK; Brownell I
Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
[TBL] [Abstract][Full Text] [Related]
38. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
[TBL] [Abstract][Full Text] [Related]
39. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
40. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro.
Krasagakis K; Fragiadaki I; Metaxari M; Krüger-Krasagakis S; Tzanakakis GN; Stathopoulos EN; Eberle J; Tavernarakis N; Tosca AD
J Cell Physiol; 2011 Apr; 226(4):1099-109. PubMed ID: 20857409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
